S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
Log in
NASDAQ:EIGR

Eiger Biopharmaceuticals Stock Forecast, Price & News

$9.89
+0.61 (+6.57 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.10
Now: $9.89
$9.93
50-Day Range
$9.28
MA: $10.84
$12.42
52-Week Range
$4.55
Now: $9.89
$15.82
Volume258,506 shs
Average Volume391,431 shs
Market Capitalization$289.21 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Read More
Eiger Biopharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.05 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-272-6138

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.31 per share

Profitability

Net Income$-70,250,000.00

Miscellaneous

Employees18
Market Cap$289.21 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$9.89
+0.61 (+6.57 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

How has Eiger Biopharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Eiger Biopharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EIGR shares have increased by 45.2% and is now trading at $9.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Eiger Biopharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eiger Biopharmaceuticals
.

When is Eiger Biopharmaceuticals' next earnings date?

Eiger Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Eiger Biopharmaceuticals
.

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) released its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.60) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.71) by $0.11.
View Eiger Biopharmaceuticals' earnings history
.

What price target have analysts set for EIGR?

3 brokerages have issued 12 month target prices for Eiger Biopharmaceuticals' stock. Their forecasts range from $31.00 to $32.00. On average, they anticipate Eiger Biopharmaceuticals' stock price to reach $31.50 in the next year. This suggests a possible upside of 218.5% from the stock's current price.
View analysts' price targets for Eiger Biopharmaceuticals
.

Who are some of Eiger Biopharmaceuticals' key competitors?

What other stocks do shareholders of Eiger Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger Biopharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Gilead Sciences (GILD), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Verastem (VSTM).

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the following people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)
  • Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)
  • Mr. James P. Shaffer, Chief Bus. Officer (Age 52)
  • Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 38)

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger Biopharmaceuticals' major shareholders?

Eiger Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Mangrove Partners (3.24%), Cormorant Asset Management LP (2.39%), P.A.W. Capital Corp (1.20%), Goldman Sachs Group Inc. (1.01%), Two Sigma Advisers LP (0.91%) and DAVENPORT & Co LLC (0.97%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz.
View institutional ownership trends for Eiger Biopharmaceuticals
.

Which major investors are selling Eiger Biopharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Cormorant Asset Management LP, P.A.W. Capital Corp, Marshall Wace LLP, Engineers Gate Manager LP, Algert Global LLC, DAVENPORT & Co LLC, and Bank of America Corp DE.
View insider buying and selling activity for Eiger Biopharmaceuticals
.

Which major investors are buying Eiger Biopharmaceuticals stock?

EIGR stock was acquired by a variety of institutional investors in the last quarter, including Mangrove Partners, Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., Assenagon Asset Management S.A., Two Sigma Advisers LP, Trexquant Investment LP, Trellus Management Company LLC, and UBS Group AG. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton, and Thomas John Dietz.
View insider buying and selling activity for Eiger Biopharmaceuticals
.

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $9.89.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $289.21 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.

What is Eiger Biopharmaceuticals' official website?

The official website for Eiger Biopharmaceuticals is www.eigerbio.com.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.